bluebird bio (BLUE) Competitors

aTyr Pharma (NASDAQ:LIFE) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.

Which has more risk & volatility, LIFE or BLUE?

aTyr Pharma has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Which has preferable earnings & valuation, LIFE or BLUE?

aTyr Pharma has higher earnings, but lower revenue than bluebird bio. aTyr Pharma is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$350K	310.58	-$50.39M	-$0.96	-1.67
bluebird bio	$3.60M	28.03	-$266.58M	-$0.74	-1.25

Do insiders and institutionals hold more shares of LIFE or BLUE?

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 2.1% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is LIFE or BLUE more profitable?

aTyr Pharma has a net margin of 0.00% compared to aTyr Pharma's net margin of -419.64%. aTyr Pharma's return on equity of -34.32% beat bluebird bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-49.84%	-39.12%
bluebird bio	-419.64%	-34.32%	-14.44%

Do analysts recommend LIFE or BLUE?

aTyr Pharma currently has a consensus target price of $23.67, indicating a potential upside of 1,379.17%. bluebird bio has a consensus target price of $5.87, indicating a potential upside of 536.04%. Given bluebird bio's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than bluebird bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
bluebird bio	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media refer more to LIFE or BLUE?

In the previous week, bluebird bio had 8 more articles in the media than aTyr Pharma. MarketBeat recorded 10 mentions for bluebird bio and 2 mentions for aTyr Pharma. bluebird bio's average media sentiment score of 0.80 beat aTyr Pharma's score of 0.07 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
bluebird bio	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor LIFE or BLUE?

bluebird bio received 615 more outperform votes than aTyr Pharma when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 61.40% of users gave aTyr Pharma an outperform vote.

Company	Underperform	Outperform
aTyr Pharma	Outperform Votes 420 61.40%	Underperform Votes 264 38.60%
bluebird bio	Outperform Votes 1035 71.78%	Underperform Votes 407 28.22%

Summary

bluebird bio beats aTyr Pharma on 10 of the 18 factors compared between the two stocks.